j.park

j.park Palantir Co-Founder Joe Lonsdale Cheers Trump's New SEC Pick, Calls Out Gary Gensler For 'Purposely' Not Defining Crypto RulesMan City crisis continues as Feyenoord come from three down to draw

Manchester City’s crisis deepened as they surrendered a three-goal lead late in the game to draw 3-3 against Feyenoord in the Champions League. Pep Guardiola’s side at least avoided the indignity of a sixth successive defeat in all competitions but alarm bells continue to ring at the Etihad Stadium after a dramatic late capitulation. A double from Erling Haaland – the first from the penalty spot – and a deflected effort from Ilkay Gundogan, all in the space of nine minutes either side of the break, looked to have ensured a return to winning ways. Yet Guardiola was left with his head in hands as Feyenoord roared back in the last 15 minutes with goals from Anis Hadj Moussa, Sergio Gimenez and David Hancko, two of them after Josko Gvardiol errors. City almost snatched a late winner when Jack Grealish hit the woodwork but there was no masking another dispiriting result. It was hardly the preparation City wanted for Sunday’s crunch trip to Liverpool, and the Feyenoord fans took great delight in rubbing that fact in. They sung the club anthem they share with Liverpool, You’ll Never Walk Alone, and chanted the name of their former manager Arne Slot, the current Reds boss. Guardiola arrived at the ground with a cut on the bridge of his nose and, once again, his side have been struck a nasty blow. Despite not being at their best, they had dominated early on against what seemed limited Dutch opposition. They threatened when a Gundogan shot was deflected wide and Haaland then went close to opening the scoring when he turned a header onto the post. Feyenoord goalkeeper Timon Wellenreuther gifted City another chance when he passed straight to Bernardo Silva but Grealish’s fierce volley struck team-mate Phil Foden. Foden forced a save from Wellenreuther but City had a moment of alarm when Igor Paixao got behind the defence only to shoot tamely at Ederson. Nathan Ake missed the target with a header but some luck finally went City’s way just before the break when Quinten Timber, brother of Arsenal’s Jurrien, was harshly adjudged to have fouled Haaland. The Norwegian rammed home the resulting spot-kick and City returned re-energised for the second period. They won a corner when a Matheus Nunes shot was turned behind and Gundogan fired the hosts’ second – albeit with aid of a deflection – with a firm volley from the edge of the box. City turned up the heat and claimed their third soon after as Gundogan released Nunes with a long ball and his low cross was turned into the net by a sliding Haaland. It seemed City were heading for a morale-lifting victory but a couple of Gvardiol errors changed the script. The Croatian, who had a torrid time in Saturday’s 4-0 thrashing by Tottenham, first horribly misplaced a backpass and allowed Moussa to nip in and round Ederson. Ordinarily that 75th-minute reply would have been a mere consolation and City would close out the game, but Gvardiol had another moment to forget eight minutes from time. Again he gave the ball away and Feyenoord pounced. The ball was lofted into the box and Jordan Lotomba fired a shot that glanced the post and deflected across goal, where Gimenez chested in. Ederson then blundered as he raced out of his area and was beaten by Paixao, who crossed for Hancko to head into an empty net. Amid some moments of unrest in the crowd, when objects were thrown, City tried to rally in stoppage time. Grealish had an effort deflected onto the bar but the hosts had to settle for a draw.2 Top Artificial Intelligence Stocks to Buy in December

Ange Postecoglou relishing Tottenham’s key run of fixtures before Christmas

South Korea's president avoids an impeachment attempt over martial lawThomas uses big drives and putts to hold lead in Bahamas

Watch UFC 310 Prelims: Start time, main card, free live stream

Phase 3 Study Results Demonstrated Three Year, Disease-Free Survival of 96% THOUSAND OAKS, Calif. , Dec. 7, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data demonstrating that adding BLINCYTO ® (blinatumomab) to chemotherapy significantly improves disease-free survival (DFS) in newly diagnosed pediatric patients with National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL) of average or higher risk of relapse. The data are from a Phase 3 study (AALL1731) conducted by the Children's Oncology Group. The results were simultaneously published in the New England Journal of Medicine and will be presented during the plenary session on Sunday, Dec. 8 , at 2 p.m. PT at the 66 th American Society of Hematology (ASH) Annual Meeting & Exposition in San Diego . "Over the last decade, BLINCYTO has reshaped the treatment landscape for B-ALL, offering a critical lifeline for thousands of adult and pediatric patients," said Jay Bradner , M.D., executive vice president of Research and Development and chief scientific officer at Amgen. "These powerful new data leave us little doubt about the profound impact of this medicine for a large number of children affected by this disease. We are grateful to the Children's Oncology Group, along with the patients, families and clinical teams, for their dedication and partnership in advancing this critical study to improve the lives of children with cancer." Based on the results of the first pre-specified interim analysis for efficacy, the study met its primary endpoint of DFS and study randomization was terminated early based on the recommendation from the data and safety monitoring committee due to the benefit observed in the BLINCYTO arm compared to the chemotherapy-only arm. Overall, the 3-year DFS was 96.0% for patients treated with chemotherapy plus BLINCYTO compared to 87.9% for those treated with only chemotherapy. The hazard ratio (HR) was 0.39 [95% confidence interval (CI) 0.24-0.64], indicating a 61% reduction in the risk of disease relapse, secondary malignant neoplasm or remission death with BLINCYTO. At 3 years, more patients remained alive and cancer free when treated with BLINCYTO plus chemotherapy compared to chemotherapy alone. "The AALL1731 study results are truly practice-changing, further solidifying blinatumomab's role as the standard of care for a large number of children with B-ALL," said Sumit Gupta , M.D., Ph.D., FRCPC, co-chair of the Children's Oncology Group AALL1731 study and oncologist and clinician investigator, Division of Haematology/Oncology at The Hospital for Sick Children (SickKids) and associate professor of pediatrics at the University of Toronto . "These breakthrough data showing a significant improvement in disease-free survival are poised to bring substantial clinical value to children with newly diagnosed B-ALL." The addition of BLINCYTO to chemotherapy in standard risk patients resulted in outcomes similar to those previously achieved in only the most favorable pediatric risk subsets. Among SR-Average patients, 3-year DFS was 97.5% for patients treated with BLINCYTO compared to 90.2% for those treated with only chemotherapy (HR 0.33, CI 0.15-0.69). For SR-High patients, 3-year DFS was 94.1% for those treated with BLINCYTO compared to 84.8% for those treated with only chemotherapy (HR 0.45, 95% CI 0.24-0.85). "Relapsed ALL remains a major cause of pediatric cancer mortality, with nearly half of the relapses occurring in children with standard-risk B-ALL," said Rachel E. Rau , M.D., co-chair of the Children's Oncology Group AALL1731 study, pediatric hematologist-oncologist at Seattle Children's Hospital and associate professor of pediatrics at the University of Washington . "These findings underscore the progress made with blinatumomab in preventing relapse and support its role as a critical addition to current therapeutic strategies." Safety results are consistent with the known safety profile of BLINCYTO. BLINCYTO has demonstrated a positive balance of benefits and risks, with only 0.3% of first courses associated with Grade 3+ cytokine release syndrome (CRS) and 0.7% with seizures. A higher risk of infections was observed in the BLINCYTO arm. These results provide the first evidence supporting BLINCYTO for use in the consolidation phase in newly diagnosed pediatric Philadelphia chromosome-negative (Ph-) B-ALL patients. This groundbreaking first-in-class Bispecific T-cell Engager (BiTE ® ) therapy is now backed by additional evidence reinforcing its role in redefining a standard of care for both adult and pediatric patients, starting from one month old, regardless of measurable residual disease (MRD) status. The findings further establish BLINCYTO as a versatile first-line consolidation therapy across all ages and treatment backbones. The NCI's Cancer Therapy Evaluation Program (CTEP), which sponsored the study will share data with the U.S. Food and Drug Administration as part of their ongoing communications relating to the trial. About The Children's Oncology Group The Children's Oncology Group (childrensoncologygroup.org), a member of the NCI National Clinical Trials Network (NCTN), is the world's largest organization devoted exclusively to childhood and adolescent cancer research. The Children's Oncology Group unites over 10,000 experts in childhood cancer at more than 200 leading children's hospitals, universities and cancer centers across North America , Australia , New Zealand and Saudi Arabia in the fight against childhood cancer. Today, more than 80% of the 15,000 children and adolescents diagnosed with cancer each year in the United States are cared for at Children's Oncology Group member institutions. Research performed by Children's Oncology Group institutions over the past 50 years has transformed childhood cancer from a virtually incurable disease to one with a combined 5-year survival rate of 86%. The Children's Oncology Group's mission is to improve the cure rate and outcomes for all children with cancer. About AALL1731 (NCT03914625) The AALL1731 study was a Phase 3 randomized trial to determine if two non-sequential cycles of BLINCYTO added to chemotherapy improved disease-free survival (DFS) in children with newly diagnosed pediatric National Cancer Institute (NCI) standard risk (SR) B-cell acute lymphoblastic leukemia (B-ALL). The study enrolled 4,264 newly diagnosed NCI SR B-ALL patients, of whom 2,334 were risk stratified at the end of induction therapy as either SR-Average or SR-High. At the first planned interim efficacy analysis (data cutoff June 30, 2024 ), 1,440 of the eligible and evaluable patients had been randomized. The AALL1731 study was designed and conducted independently from industry. The Cancer Therapy Evaluation Program (CTEP) of the NCI sponsored the trial and provided funding to the Children's Oncology Group to conduct the study. NCI is part of the National Institutes of Health (NIH). In addition, Amgen provided BLINCYTO and support through an NCI Cooperative Research and Development Agreement. About Acute Lymphoblastic Leukemia (ALL) ALL, also known as acute lymphoblastic leukemia, is a fast-growing type of blood cancer that develops in the bone marrow and can sometimes spread to other parts of the body, including the lymph nodes, liver, spleen and central nervous system. ALL is a rare disease, with an estimated 6,550 new cases, affecting both children and adults, diagnosed in the U.S. in 2024. 1 B-ALL begins in immature cells that would normally develop into B-cell lymphocytes, which are white blood cells that grow in bone marrow. 2,3 B-ALL is the most common type of ALL, constituting approximately 75% of cases in adults and approximately 88% in children, the most common cancer in children. 4,5 About BLINCYTO ® (blinatumomab) BLINCYTO is the first globally approved Bispecific T-cell Engager (BiTE ® ) immuno-oncology therapy that targets CD19 surface antigens on B cells. BiTE ® molecules fight cancer by helping the body's immune system detect and target malignant cells by engaging T cells (a type of white blood cell capable of killing other cells perceived as threats) to cancer cells. By bringing T cells near cancer cells, the T cells can inject toxins and trigger cancer cell death (apoptosis). BiTE ® immuno-oncology therapies are currently being investigated for their potential to treat a wide variety of cancers. BLINCYTO was granted Breakthrough Therapy and Priority Review designations by the U.S. FDA and is approved in the U.S. for the treatment of: In the European Union (EU), BLINCYTO is indicated as monotherapy for the treatment of: BLINCYTO ® IMPORTANT SAFETY INFORMATION WARNING: CYTOKINE RELEASE SYNDROME and NEUROLOGICAL TOXICITIES including IMMUNE EFFECTOR CELL-ASSOCIATED NEUROTOXICITY SYNDROME Contraindications BLINCYTO ® is contraindicated in patients with a known hypersensitivity to blinatumomab or to any component of the product formulation. Warnings and Precautions Adverse Reactions Dosage and Administration Guidelines INDICATIONS BLINCYTO ® (blinatumomab) is indicated for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in adult and pediatric patients one month and older with: Please see BLINCYTO ® full Prescribing Information , including BOXED WARNINGS. About Bispecific T-Cell Engager (BiTE ® ) Technology BiTE technology is a targeted immuno-oncology platform that is designed to engage a patient's own T cells to any tumor-specific antigen, activating the cytotoxic potential of T cells to eliminate detectable cancer. The BiTE immuno-oncology platform has the potential to treat different cancer types through tumor-specific antigens. The BiTE platform has a goal of leading to off-the-shelf solutions, which have the potential to make innovative T-cell treatment available to all providers when their patients need it. For more than a decade, Amgen has been advancing this innovative technology, which has demonstrated strong efficacy in hematological malignancies and now a solid tumor with the approval of IMDELLTRA. Amgen remains committed to progressing multiple BiTE molecules across a broad range of hematologic and solid tumor malignancies, paving the way for additional applications in more tumor types. Amgen is further investigating BiTE technology with the goal of enhancing patient experience and therapeutic potential. To learn more about BiTE technology, visit BiTE ® Technology 101 . About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. For more information, visit Amgen.com and follow Amgen on X , LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), Amgen's acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on Amgen's acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on Amgen's business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including its most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those Amgen projects. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, preclinical results do not guarantee safe and effective performance of product candidates in humans. The complexity of the human body cannot be perfectly, or sometimes, even adequately modeled by computer or cell culture systems or animal models. The length of time that it takes for Amgen to complete clinical trials and obtain regulatory approval for product marketing has in the past varied and Amgen expects similar variability in the future. Even when clinical trials are successful, regulatory authorities may question the sufficiency for approval of the trial endpoints Amgen has selected. Amgen develops product candidates internally and through licensing collaborations, partnerships and joint ventures. Product candidates that are derived from relationships may be subject to disputes between the parties or may prove to be not as effective or as safe as Amgen may have believed at the time of entering into such relationship. Also, Amgen or others could identify safety, side effects or manufacturing problems with its products, including its devices, after they are on the market. Amgen's results may be affected by its ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing its products and global economic conditions. In addition, sales of Amgen's products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, Amgen's research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. Amgen's business may be impacted by government investigations, litigation and product liability claims. In addition, Amgen's business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If Amgen fails to meet the compliance obligations in the corporate integrity agreement between Amgen and the U.S. government, Amgen could become subject to significant sanctions. Further, while Amgen routinely obtains patents for its products and technology, the protection offered by its patents and patent applications may be challenged, invalidated or circumvented by its competitors, or Amgen may fail to prevail in present and future intellectual property litigation. Amgen performs a substantial amount of its commercial manufacturing activities at a few key facilities, including in Puerto Rico, and also depends on third parties for a portion of its manufacturing activities, and limits on supply may constrain sales of certain of its current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for Amgen's manufacturing activities, the distribution of Amgen's products, the commercialization of Amgen's product candidates, and Amgen's clinical trial operations, and any such events may have a material adverse effect on Amgen's product development, product sales, business and results of operations. Amgen relies on collaborations with third parties for the development of some of its product candidates and for the commercialization and sales of some of its commercial products. In addition, Amgen competes with other companies with respect to many of its marketed products as well as for the discovery and development of new products. Further, some raw materials, medical devices and component parts for Amgen's products are supplied by sole third-party suppliers. Certain of Amgen's distributors, customers and payers have substantial purchasing leverage in their dealings with Amgen. The discovery of significant problems with a product similar to one of Amgen's products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on its business and results of operations. Amgen's efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology Amgen has acquired, may not be successful. There can be no guarantee that Amgen will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. Amgen may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of Amgen's information technology systems could compromise the confidentiality, integrity and availability of Amgen's systems and Amgen's data. Amgen's stock price may be volatile and may be affected by a number of events. Amgen's business and operations may be negatively affected by the failure, or perceived failure, of achieving its environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect Amgen's business and operations. Global economic conditions may magnify certain risks that affect Amgen's business. Amgen's business performance could affect or limit the ability of the Amgen Board of Directors to declare a dividend or its ability to pay a dividend or repurchase its common stock. Amgen may not be able to access the capital and credit markets on terms that are favorable to it, or at all. Any scientific information discussed in this news release relating to new indications for Amgen's products is preliminary and investigative and is not part of the labeling approved by the U.S. Food and Drug Administration for the products. The products are not approved for the investigational use(s) discussed in this news release, and no conclusions can or should be drawn regarding the safety or effectiveness of the products for these uses. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) References View original content to download multimedia: https://www.prnewswire.com/news-releases/blincyto-blinatumomab-added-to-chemotherapy-significantly-improves-survival-in-newly-diagnosed-pediatric-patients-with-b-cell-precursor-acute-lymphoblastic-leukemia-b-all-302325381.html SOURCE AmgenIsrael and Lebanon's Hezbollah start a ceasefire after nearly 14 months of fighting

The ruling All Progressives Congress has warned that no alliance of the opposition leaders, including former Vice President Atiku Abubakar and former Anambra Governor Peter Obi, will be potent enough to stop President Bola Tinubu’s re-election in 2027. The warning was given by the National Publicity Director of APC, Bala Ibrahim, in an exclusive interview with The PUNCH on Tuesday. Ibrahim was reacting to a statement by Atiku’s spokesperson, Paul Ibe, that both his principal and his Labour Party counterpart had learnt their lessons in the last general elections and would unite to kick out the “incompetent and clueless” administration of the APC. According to him, the combined votes of the two leaders, which would have amounted to 12 million, should have been enough to stop the President and prevent the hardship he has meted out to Nigerians. Ibe expressed his views on Monday’s edition of Channels Television’s Politics Today. Reactions have trailed the interview with major opposition agreeing that a coalition of forces or merger could indeed defeat the APC in the same manner as the one witnessed in 2015 when former President Muhammadu Buhari defeated a sitting President, Goodluck Jonathan. When contacted, Obi’s media aide, Umar Ibrahim, emphasised that his principal was committed to a better Nigeria and would be willing to collaborate with anyone who shared his vision, as long as their desire isn’t state capture. Ibrahim said, “This dedication stems from his unshakeable optimism in the country’s potential and his focus on the welfare and prosperity of all citizens. Regarding Paul Ibe’s statement about Atiku’s willingness to unite with Obi, it’s clear that both leaders are open to working together to save Nigeria from the APC-led administration’s tyranny. “However, Obi’s commitment to collaboration isn’t limited to any particular individual or party.” On its part, the opposition political parties in Nigeria under the aegis of the Coalition of United Political Parties and the Social Democratic Party have expressed concerns, saying the country needed more than a coalition between the 2023 presidential candidates of the Peoples Democratic Party and the Labour Party. CUPP and SDP stated that to defeat the APC, Nigerians must demand credible elections and form a coalition of trustworthy leaders to spearhead a rescue movement that served the nation’s collective interest. In an exclusive interview with The PUNCH, CUPP National Secretary, Peter Ahmeh acknowledged that a coalition could aid opposition parties in defeating the APC. Ahmeh emphasised that the key coalition needed at this time was one focused on ensuring free and fair elections. He stated, “Our country has its ways. Atiku is a wonderful leader in Nigeria. That is very important. But the fact is there will be some sentiments that will come into play if you don’t put a person from southern Nigeria on the ballot. If you don’t do that, the idea that the northerners have taken over their eight years will now become part of the discussion across southwestern, southeastern, and South-South Nigeria. “So, what we should do is believe that at the end of the day, these two leaders and other leaders will find common ground, where they will put the interest of Nigeria before their personal interests, allowing us to win this election and determine the future of Nigeria in a way that will benefit all Nigerians.” Reacting to the possibility of a coalition between Atiku and Obi’s group to defeat the APC, he stated that in addition to a coalition, Nigerians must demand that elections be decided and concluded at the polling unit. He added, “Yes, a coalition can help the opposition party defeat the APC. There’s no doubt about that. It will also facilitate the easy defeat of the APC. “But the most important coalition we need at this moment is one that ensures elections are free and fair. Because if we do that, even when people form a coalition, we still face the problem of draconian leadership that can cause glitches in the server, or manipulate election results without proper authority behind it. The solution is that our elections should be decided by the polling unit. “The Republic of Ghana has shown this. If you look at the commission chairperson, votes are cast at the polling unit, votes are recorded at the polling unit, and winners are announced at the polling unit. We should do away with these coalition centres, which are fraudulent centres for the manipulation of results. “We still believe that when the people are determined and stay true to their convictions, the electorate will go to the polling unit and make their decision. But a coalition will only facilitate and make it easier for the opposition to reach the Presidency.” The National Chairman of SDP, Shehu Gabam, stated that a coalition may not be the right solution at this time. In an exclusive interview with The PUNCH on Tuesday, Gabam explained that political parties had struggled to unite over a long period, resulting in a trust deficit that affects most parties, with only a few exceptions. He stated, “The coalition will not do much right now. The decay is extremely bad, and the loss of gravity in the political space is another point of concern. What people are looking forward to is the assembly of credible individuals to form a rescue movement that is credible and has a solid base; this has nothing to do with the coalition of political parties. “The parties, over a long period of time, could not galvanise themselves. The trust deficit has enveloped the various political parties, apart from a few. Even if you merge all the parties, the roles of individuals who are good, credible, and have been tested will draw people, not the roles of the political parties. “There is a trust deficit, and this may lead to a crisis among various political parties. What the people are looking for are individuals who have a record of service and the ability to be creative. Regarding Atiku and Obi, he said, “All I know is that every hand is needed to be on board to salvage the situation. We are talking about salvaging Nigeria. And the knowledge required to do that is not domiciled in a single individual. We have a multitude of talents in the country, with the energy and capacity to turn things around for good; it’s just that they have not been organised. “So, for me, what is critical is to focus on the individuals, the energy sector, and their intellectual base to harness the strength in our diversity for the benefit of all.” Similarly, the All Progressives Grand Alliance said it was ready to form an alliance with other progressive political forces across party lines to build a Nigeria that citizens could be proud of. The National Chairman of APGA, Sly Ezeokenwa, made this known while briefing newsmen in Abuja, echoing similar sentiments expressed by the party’s National Leader and Anambra State Governor, Charles Soludo. Ezeokenwa stated that with the party’s internal leadership tussle resolved by a Supreme Court judgment affirming his chairmanship, APGA was now poised to reclaim its position in Nigeria’s political landscape. “APGA proudly has elected representatives within and outside the South East. We are ready and willing to work with all other progressives to build Nigeria because we believe in our country. “As part of our commitment to reconciliation, we have granted amnesty to party members who are genuinely repentant, irrespective of which side they supported during the crisis,” he said. But Bala Ibrahim laughed at the thought of both Atiku and Obi, who he described as strange bedfellows, coming together with the sole aim of stopping Tinubu in the 2027 election. The APC spokesman also said no potential from the opposition, who he said are enmeshed in crisis, can seriously pose any serious threat to the ruling party. He said, “It is a dream gone wrong. All over the world, you don’t add up the total votes in an election and hope to use it to topple the votes of the winner. No! You don’t do that. A smart winner always capitalises on that to create a crack within the opposition. This is because each candidate is aspiring to win. “It’s a case of the simple majority providing the winner so far as he meets the requirement and whatever percentage is needed. So, if this is what they are relying upon, then we start celebrating 2027 because they are going to be defeated again. They will be severely beaten. “We are happy they are learning lessons from the superior antics of the ruling APC. Now that they have admitted they are learning from those lessons, they should wait for new tutorials in 2027. As a matter of fact, the APC has opened a Progressive Institute where they can come with their books and biro to learn more about progressivism.” Also, in an exclusive interview with one of our correspondents on Tuesday, the PDP Deputy National Youth Leader, Timothy Osadolor, explained that both the former Vice President and the former Governor of Anambra State were partly to blame for the hardships Nigerians were currently facing. Osadolor called the potential unity between Atiku and Obi an illusion, noting that neither has demonstrated a commitment to collaborating. “Atiku and Obi coming together is still illusionary because they have not committed themselves to coming together. “If they go ahead and come together, they will provide a viable alternative to this APC-failed administration. “The truth is that Atiku has paid his dues, and Obi has also paid his dues. Both of them contributed to where we are now. If they had united in the last election, Nigeria and Nigerians would not be in the current pain we are in now. “But for 2027, anybody with his head on his shoulders will be better than President Bola Tinubu. Atiku and Obi will be a welcome development if they agree to work together and manage their egos. But I believe there will be more viable options that we can pick from. “Atiku brought Obi to the light in 2019, so what Obi searched for and couldn’t find in 2023, he may also want to search for the same thing in 2027. So, for me, it is an ego issue. If Obi can manage his ego and if Atiku can open his heart more, they stand a chance, but I will not foreclose Nigeria’s liberation on them.”A COMPLETE UNKNOWN (TBC) 140mins ★★★★☆ THERE are five words that can make an audience’s blood run cold when watching a beloved singer: “This is a new one.” But not, it would seem, for Bob Dylan fans. They have long been used to the guitar-playing genius refusing to conform to popular demands and play, well, his biggest hits. Now, the story behind this intriguing musical mystery has dared to be made, with a gentle insight into his now-famous unconventional style over the first four years of his career. Opening in 1961, we meet a 19-year-old Dylan ( Timothee Chalamet ) with guitar in hand, traipsing through the filthy streets of New York having arrived from Minnesota. Looking pale and weary, he makes his way to a hospital that is the home of political folk singer and songwriter of the then highly controversial This Land Is Your Land — Woody Guthrie (Scoot McNairy). READ MORE IN TV By his bedside is fellow folk singer, Pete Seeger ( Edward Norton ) and Dylan performs one of his songs to them both. The pair recognise his raw talent and he is soon taken in by Seeger and the folk singing community, There, Dylan starts playing dingy open mics and church services, where he meets girlfriend Sylvie Russo ( Elle Fanning ) — real name Suze Rotolo, but changed for the film . She is seen famously clutching Dylan’s arm on the cover of his album, The Freewheelin’. Most read in Film Sylvie is sharp, political and part of the bohemian scene in New York’s Greenwich Village. Bob instantly moves into her small apartment, bringing with him some photo albums showing his real name, Robert Zimmerman. The only reference to his life before the move. At Sylvie’s, Bob wakes up at all hours of the night to scrawl songs on scraps of paper and generally behaves like a moody, bad boyfriend. One of the reasons for this is his relationship with fellow singer and activist, Joan Baez ( Top Gun: Maverick ’s Monica Barbaro). The pair soon make beautiful music together, on stage and off. But Dylan cannot be relied upon emotionally by either of the women. There is only room for one person in his life. And that is Bob Dylan. Directed by Oscar nominated James Mangold ( Walk The Line ), it delicately examines the life of a man who is burdened by his own talent. He loathes fame, yet can’t help getting on stage and showing it off to the masses. He’s a complicated beast and Chalamet does a stunning job of bringing life to a difficult role that he clearly knows will have superfans dissecting every word spoken. His singing and playing is immaculate, with Dylan’s back catalogue of 40 songs performed with breathtaking imitation. Norton and Barbaro also both stand out. The sets and style are deliciously detailed with an exquisite, sepia colour palette. You can feel the excitement of a new, vibrant music scene sweeping through the basement clubs of New York, while the rest of the US was under the fear of the Cold War looming. The sets and style are deliciously detailed with an exquisite, sepia colour palette JFK was assassinated, Martin Luther King delivered ‘I Have A Dream’ and all this caused creativity to seep from the pores of the young, talented political rebels. The women, sadly, are not well-written, rounded characters. I couldn’t fathom why Sylvie adored Bob with such faithful love when no warmth between them was ever shown. He treated her badly from the beginning and she stands on the sidelines weeping. It feels unlikely for such a strong, ambitious woman. The film culminates at the famous Newport Folk Festival performance where Bob, loved for his acoustic music, decides to play an entirely new set of songs with electric instruments. Much to the crowd’s dismay. So after two and a half hours, do you know much more about the elusive rebel that is Bob Dylan? A little. READ MORE SUN STORIES Yet it’s still enjoyable watching this elusive star remain a complete unknown. In cinemas on January 17.